Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Reversal of increases in methadone distribution for opioid use disorder in the US during the COVID-19 pandemic

View ORCID ProfileAmy L. Kennalley, Jessica L. Fanelli, John A. Furst Jr., Nicholas J. Mynarski, Margaret A. Jarvis, Stephanie D. Nichols, Kenneth L. McCall, Brian J. Piper
doi: https://doi.org/10.1101/2022.03.09.22272154
Amy L. Kennalley
aDepartment of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amy L. Kennalley
  • For correspondence: amykennalley{at}gmail.com akennalley{at}som.geisinger.edu
Jessica L. Fanelli
aDepartment of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Furst Jr.
aDepartment of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas J. Mynarski
aDepartment of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret A. Jarvis
bGeisinger Clinic, Geisinger, Danville, PA, 17821
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie D. Nichols
cDepartment of Pharmacy Practice, University of New England, Portland, ME 04103
PharmD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth L. McCall
dDepartment of Pharmacy Practice, Binghamton University, Johnson City, NY 13790
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Piper
aDepartment of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510
eCenter for Pharmacy Innovation and Outcomes, Forty Fort, PA, 18704
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Opioid use disorder (OUD) is a major public health concern in the United States (US), resulting in high rates of overdose and other negative outcomes. Methadone, a treatment for OUD, has been shown to be effective in reducing the risk of overdose and improving overall health and quality of life. This study analyzed the distribution of methadone for the treatment of OUD across the US using data from the Drug Enforcement Administration’s Automated Reports and Consolidated Ordering System, Medicaid’s State Drug Utilization Data, and the US Census Bureau. Analysis revealed that methadone distribution for OUD has expanded significantly over the past decade, with an average state increase of +96.96% from 2010 to 2020, and there was a significant increase in overall distribution of methadone to opioid treatment programs (OTP) in the US from 2010 to 2020 (+61.00%) and from 2015 to 2020 (+26.22%). However, the distribution to OTPs did not significantly change from 2019 to 2021 (−5.15%). Furthermore, pronounced variation in methadone distribution among states were observed, with some states having no OTPs or Medicaid coverage. New policies are urgently needed to increase access to methadone treatment and address the opioid overdose crisis in the US.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

  • Declarations of interest: BJP is supported by the Health Resources Services Administration (D34HP31025), the Pennsylvania Academic Clinical Research Center, and was (until 12/31/2021) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.

  • Medicaid data for three states was excessively high, presumably due to a CMS or state-level data-input error.

Data Availability

All data produced are available online at the DEA's Automated Reports and Consolidated Ordering System and Medicaid's State Drug Utilization Data.

https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html

https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medicaid.gov%2Fmedicaid%2Fprescription-drugs%2Fstate-drug-utilization-data%2Findex.html&data=05%7C01%7CAKennalley%40som.geisinger.edu%7Cbf1fa1b23daa469ac51f08daaec32aad%7Cc048947985ac4b82bbad54c03fc21678%7C0%7C0%7C638014450845928960%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=xZLVJRHiS%2BoukxF0vELEvnUhD2aSrTwo3sz5u%2BV7fig%3D&reserved=0

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 15, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Reversal of increases in methadone distribution for opioid use disorder in the US during the COVID-19 pandemic
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Reversal of increases in methadone distribution for opioid use disorder in the US during the COVID-19 pandemic
Amy L. Kennalley, Jessica L. Fanelli, John A. Furst Jr., Nicholas J. Mynarski, Margaret A. Jarvis, Stephanie D. Nichols, Kenneth L. McCall, Brian J. Piper
medRxiv 2022.03.09.22272154; doi: https://doi.org/10.1101/2022.03.09.22272154
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Reversal of increases in methadone distribution for opioid use disorder in the US during the COVID-19 pandemic
Amy L. Kennalley, Jessica L. Fanelli, John A. Furst Jr., Nicholas J. Mynarski, Margaret A. Jarvis, Stephanie D. Nichols, Kenneth L. McCall, Brian J. Piper
medRxiv 2022.03.09.22272154; doi: https://doi.org/10.1101/2022.03.09.22272154

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Addiction Medicine
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)